Full-court press on SA. Here is my comment refutin

Full-court press on SA. Here is my comment refuting one of our favorite bashers, who is using yet another name there. It's obvious from my response what his claims were, so I won't re-post his lies.

Quote:

---

You are wrong about the duration of the trial. The FDA asked for an almost unbelievable 3 THOUSAND patients to be in the trial. Given that you would have to have many, many clinical trial sites, and that patients would have to meet certain very specific criteria, and that this is not something that you can just walk into a hospital every day and find patients who meet those criteria -- yes, it would take a long time to recruit patients for this trial. You are absolutely incorrect in your claim that only a couple hundred patients would be needed -- absolutely, utterly wrong.
As far as the expense, 30 million dollars is not a lot for, for instance, Pfizer or Merck, but it would exceedingly foolish for a small company to issue 30 million dollars worth of stock, diluting the stock by abou 25%, when instead they can run FOUR clinical trials for a few million dollars total. Speaking as an actual shareholder, I am happy that the company chose to spend a few million dollars to do multiple clinical trials, all of which thus far have been successful, rather than taking a couple of years, diluting the stock tremendously, and gambling on the results of the ABSSSi -- and then waiting how knows long after that to strike a deal with a Big Pharma.
Instead, we have at least 2 clinical trials RIGHT NOW with results that warrant a deal by one of the many pipeline-starved Big Pharmas, with results from two more potential blockbuster drugs to come in the near future.
It is a fallacious conclusion to claim that a company's decision to defer the very 3,000-patient, $30Million, very lengthy Brilacidin-ABSSSI was caused by anything but what they stated:
that the resources were better spent for multiple quick clinical trials, at far less expense. A financially-prudent company does this, and careful investors look for signs of financial prudence in the management.

---